SUBMIT MANUSCRIPT

Donnish Journal of Biomedical Research

August 2016 Vol. 3(2), pp. 013-018

ISSN: 2984-8954

Copyright © 2016 Donnish Journals




Original Research Paper


Effect of Helicobacter pylori on Treatment of Hepatitis C Virus Egyptian Patients


Naglaa Kamal Madkour1*, Azza M.S. Ghanem2, Sahar Y.H. El-melegy3, Mohamed O. Abdel-Moneim3, Soheir S. Abdel-Salam3, Ghada Hussein4, Nahla S Kotb5 and Mohamed A. Attala6

1Zoology Department, Girls College for Arts, Science and Education, Ain Shams University, Cairo, Egypt.
2Immunology Department, Faculty of Medicine, AL-Azhar University, Cairo, Egypt.
3Bacteriology Department, Faculty of Science, Benha University, Egypt.
4Cilinical Pathology Department, National Institute of Diabetes and Endocrinology, Egypt.
5Biochemistry Department, National Organization for Research and Control of Biological product, Egypt.
6Tropical Department, National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt.

Corresponding Author: Naglaa Kamal Madkour

Accepted 24th July, 2016.



Abstract


Background: Hepatitis C virus (HCV) is considered the most common etiology of chronic liver disease in Egypt, which may progress to cirrhosis and hepatocellular carcinoma (HCC). Previous studies have documented an association between Helicobacter pylori (H. pylori) infection and HCV. Objective: This study aimed to investigate the role of Helicobacter pylori (H. pylori) seropositivity in the treatment of patients with hepatitis C virus (HCV) infection and the effect of this co-infection on response to interferon-α and ribavirin therapy. Methods: The presence of (H. pylori) was tested using a commercially available enzyme immunoassay in serum samples from 49 patients with chronic hepatitis C. Clinical features, HCV markers and response of HCV to interferon-α and ribavirin therapy were compared between (H. pylori) seropositivity and (H. pylori) seronegativity patients. Results: (H. pylori) antigen was detected in 24(49.0%) of 50 HCV patients. There was no association between (H. pylori) seropositivity in the liver and age, gender of patients, liver function tests, AFP levels or viral load. The sustained response rate for HCV clearance following interferon-α and ribavirin treatment did not differ between patients with and without anti-(H. pylori) seropositivity. Conclusion: No correlation between coexistent (H. pylori) infection and clinical course of Hepatitis C Virus and suggest an association between this bacterium and progression of liver fibrosis.

Keywords: Helicobacter pylori, Hepatitis C virus, Interferon, Ribavirin.

Read: [Full Text - PDF]


Cite This Article:

Naglaa Kamal Madkour, Azza M.S. Ghanem, Sahar Y.H. El-melegy, Mohamed O. Abdel-Moneim, Soheir S. Abdel-Salam, Ghada Hussein, Nahla S. Kotb and Mohamed A. Attala. Effect of Helicobacter pylori on Treatment of Hepatitis C Virus Egyptian Patients. Donnish Journal of Biomedical Research 3(2) 2016 pp. 013-018.


© 2016 - Donnish Journals | Terms | Privacy policy |